Fructosamine huyết thanh và albumin glycosyl hóa và nguy cơ tử vong cũng như kết quả lâm sàng ở bệnh nhân thẩm phân máu

Diabetes Care - Tập 36 Số 6 - Trang 1522-1533 - 2013
Tariq Shafi1,2, Stephen M. Sozio1,2, Laura Plantinga3, Bernard G. Jaar4,1,5,2, Edward T. Kim6, Rulan S. Parekh4,1,7, Michael W. Steffes8, Neil R. Powe4,1,9, Josef Coresh4,3,1,2, Elizabeth Selvin4,1,2
1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
2Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Medical Institutions, Baltimore, Maryland
3Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia
4Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
5Nephrology Center of Maryland, Baltimore, Maryland
6Diablo Nephrology Medical Group, San Francisco, California
7Departments of Pediatrics, Hospital for Sick Children and Medicine, University Health Network, and University of Toronto, Toronto, Canada
8Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota
9Department of Medicine, San Francisco General Hospital and University of California, San Francisco, San Francisco, California

Tóm tắt

MỤC TIÊU

Các xét nghiệm đo tổng các protein glycosyl hóa trong huyết thanh (fructosamine) và albumin glycosyl hóa cụ thể hơn có thể là những chỉ số hữu ích cho tình trạng tăng đường huyết ở bệnh nhân thẩm phân, hoặc là sự thay thế hoặc bổ sung cho các chỉ số tiêu chuẩn như hemoglobin A1c, vì chúng không bị ảnh hưởng bởi quá trình tái tạo hồng cầu. Tuy nhiên, mối quan hệ của chúng với các kết quả lâu dài ở bệnh nhân thẩm phân chưa được mô tả rõ ràng.

THIẾT KẾ NGHIÊN CỨU VÀ PHƯƠNG PHÁP

Chúng tôi đã đo fructosamine và albumin glycosyl hóa trong các mẫu ban đầu từ 503 người tham gia thẩm phân máu mới vào một nghiên cứu đoàn hệ tiến cứu quốc gia, được tuyển chọn từ năm 1995–1998 và theo dõi trung bình là 3,5 năm. Các kết quả bao gồm tỷ lệ tử vong và tỷ lệ mắc bệnh do mọi nguyên nhân và bệnh tim mạch (CVD) (sự kiện CVD đầu tiên và nhập viện do nhiễm trùng huyết đầu tiên) được phân tích bằng hồi quy Cox, điều chỉnh theo đặc điểm nhân khẩu học và lâm sàng, cũng như các bệnh đi kèm.

Từ khóa

#Fructosamine #albumin glycosyl hóa #thẩm phân máu #tử vong #bệnh tim mạch #xét nghiệm huyết thanh.

Tài liệu tham khảo

U.S. Renal Data System, 2011, USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States

Mehrotra, 2011, Assessment of glycemic control in dialysis patients with diabetes: glycosylated hemoglobin or glycated albumin?, Clin J Am Soc Nephrol, 6, 1520, 10.2215/CJN.04210511

Freedman, 2010, Comparison of glycated albumin and hemoglobin A1c concentrations in diabetic subjects on peritoneal and hemodialysis, Perit Dial Int, 30, 72, 10.3747/pdi.2008.00243

Peacock, 2008, Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis, Kidney Int, 73, 1062, 10.1038/ki.2008.25

Armbruster, 1987, Fructosamine: structure, analysis, and clinical usefulness, Clin Chem, 33, 2153, 10.1093/clinchem/33.12.2153

Koga, 2010, Clinical impact of glycated albumin as another glycemic control marker, Endocr J, 57, 751, 10.1507/endocrj.K10E-138

Ricks, 2012, Glycemic control and cardiovascular mortality in hemodialysis patients with diabetes: a 6-year cohort study, Diabetes, 61, 708, 10.2337/db11-1015

Williams, 2006, Hemodialyzed type I and type II diabetic patients in the US: characteristics, glycemic control, and survival, Kidney Int, 70, 1503, 10.1038/sj.ki.5001789

Powe, 1996, Choices for healthy outcomes in caring for end stage renal disease, Semin Dial, 9, 9, 10.1111/j.1525-139X.1996.tb00890.x

Longenecker, 2005, High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients, J Am Soc Nephrol, 16, 1794, 10.1681/ASN.2004110922

Miskulin, 2002, Comorbidity and other factors associated with modality selection in incident dialysis patients: the CHOICE Study. Choices for Healthy Outcomes in Caring for End-Stage Renal Disease, Am J Kidney Dis, 39, 324, 10.1053/ajkd.2002.30552

Athienites, 2000, Comorbidity assessment in hemodialysis and peritoneal dialysis using the index of coexistent disease, Semin Dial, 13, 320, 10.1046/j.1525-139x.2000.00095.x

Liu, 2004, Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition, JAMA, 291, 451, 10.1001/jama.291.4.451

Singer, 2003, Applied Longitudinal Data Analysis, 10.1093/acprof:oso/9780195152968.001.0001

Kalantar-Zadeh, 2007, A1C and survival in maintenance hemodialysis patients, Diabetes Care, 30, 1049, 10.2337/dc06-2127

Duong, 2011, Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus, Clin J Am Soc Nephrol, 6, 1041, 10.2215/CJN.08921010

Freedman, 2011, Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients, Clin J Am Soc Nephrol, 6, 1635, 10.2215/CJN.11491210

Shurraw, 2010, Glycemic control and the risk of death in 1,484 patients receiving maintenance hemodialysis, Am J Kidney Dis, 55, 875, 10.1053/j.ajkd.2009.12.038

Freedman, 2012, A critical evaluation of glycated protein parameters in advanced nephropathy: a matter of life or death: time to dispense with the hemoglobin A1C in end-stage kidney disease, Diabetes Care, 35, 1621, 10.2337/dc12-0027

Kalantar-Zadeh, 2012, A critical evaluation of glycated protein parameters in advanced nephropathy: a matter of life or death: A1C remains the gold standard outcome predictor in diabetic dialysis patients. Counterpoint, Diabetes Care, 35, 1625, 10.2337/dc12-0483

Kim, 2011, Glycated albumin may be a possible alternative to hemoglobin A1c in diabetic patients with anemia, Clin Chem Lab Med, 49, 1743, 10.1515/CCLM.2011.646

Shima, 2012, Lower value of glycated haemoglobin relative to glycaemic control in diabetic patients with end-stage renal disease not on haemodialysis, Ann Clin Biochem, 49, 68, 10.1258/acb.2011.011161

Ansari, 2003, Assessing glycemic control in patients with diabetes and end-stage renal failure, Am J Kidney Dis, 41, 523, 10.1053/ajkd.2003.50114

Kouzuma, 2004, Study of glycated amino acid elimination reaction for an improved enzymatic glycated albumin measurement method, Clin Chim Acta, 346, 135, 10.1016/j.cccn.2004.02.019

Inaba, 2007, Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection, J Am Soc Nephrol, 18, 896, 10.1681/ASN.2006070772

Ichikawa, 1996, What is the best index of glycemic control in patients with diabetes mellitus on hemodialysis?, Nippon Jinzo Gakkai Shi, 38, 305

Mittman, 2010, Serum fructosamine versus glycosylated hemoglobin as an index of glycemic control, hospitalization, and infection in diabetic hemodialysis patients, Kidney Int Suppl, S41, 10.1038/ki.2010.193

Selvin, 2011, Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes, Diabetes, 60, 298, 10.2337/db10-1198

Selvin, 2010, Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults, N Engl J Med, 362, 800, 10.1056/NEJMoa0908359